Oxymetazoline nasal Pregnancy and Breastfeeding Warnings
Oxymetazoline nasal is also known as: 12 Hour Nasal Decongestant, Afrin, Afrin NoDrip Original, Afrin Original, Afrin Severe Congestion, Afrin Sinus, Dristan 12 Hour Nasal Spray, Four-Way Nasal Spray, Mucinex Sinus-Max Full Force, Mucinex Sinus-Max Moisture Smart, NRS Nasal, Neo-Synephrine 12 Hour, Nostrilla, Nostrilla 12 Hour, Oxyfrin, Oxymeta-12, Sudafed OM Sinus Cold, Sudafed OM Sinus Congestion, Todays Health Nasal Relief Extra Moisturizing, Vicks QlearQuil 12 Hour Nasal Decongestant Moisturizing Spray, Vicks Sinex 12-Hour Decongestant Nasal Spray, Vicks Sinex 12-Hour Decongestant UltraFine Mist, Vicks Sinex Moisturizing 12-Hour Decongestant UltraFine Mist, Zicam Extreme Congestion Relief, Zicam Sinus Relief
Oxymetazoline nasal Pregnancy Warnings
Oxymetazoline nasal has been assigned to pregnancy category C by the FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. Oxymetazoline nasal is only recommended for use during pregnancy when benefit outweighs risk.
The Collaborative Perinatal Project has reported 2 cases of exposure to oxymetazoline nasal in pregnant women (n = 50,282 mother-child pairs) resulting in no apparent teratogenicity. However, the number of women exposed is too small for any definite conclusion. A case report involving a 20-year-old woman at 41 weeks' gestation reported late fetal heart rate decelerations 30 minutes following administration of oxymetazoline 0.05% to the mother at a dose of 2 sprays to each nostril. This was the mother's sixth dose of oxymetazoline nasal in 15.5 hours. Oxymetazoline nasal is recommended to be dosed no less than every 12 hours. The fetal heart rate returned to normal and a normally developed infant was spontaneously delivered at approximately 6 hours and 14 hours following the last dose, respectively. The findings of 12 women between 27 and 39 week's gestation receiving oxymetazoline nasal 0.05% as a single dose of 2 squirts reported no changes in maternal blood pressures or pulse rates, fetal aortic blood flow velocity, fetal heart rate, or the systolic-to-diastolic ratios in the uterine arcuate artery and umbilical artery when measured at 15-minute intervals for 2 hours following administration. The authors, however, did caution against the use of oxymetazoline in pregnant women with borderline placental reserve.
Oxymetazoline nasal Breastfeeding Warnings
There are no data on the excretion of oxymetazoline nasal into human milk.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.